BR112021015737A2 - Formulações de 4-(7-hidróxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrila - Google Patents
Formulações de 4-(7-hidróxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrila Download PDFInfo
- Publication number
- BR112021015737A2 BR112021015737A2 BR112021015737-9A BR112021015737A BR112021015737A2 BR 112021015737 A2 BR112021015737 A2 BR 112021015737A2 BR 112021015737 A BR112021015737 A BR 112021015737A BR 112021015737 A2 BR112021015737 A2 BR 112021015737A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formulation
- pain
- salt
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806705P | 2019-02-15 | 2019-02-15 | |
| US62/806,705 | 2019-02-15 | ||
| PCT/IB2020/051211 WO2020165839A1 (en) | 2019-02-15 | 2020-02-13 | Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021015737A2 true BR112021015737A2 (pt) | 2021-10-26 |
Family
ID=69740424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021015737-9A BR112021015737A2 (pt) | 2019-02-15 | 2020-02-13 | Formulações de 4-(7-hidróxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrila |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US11478480B2 (https=) |
| EP (1) | EP3923912A1 (https=) |
| JP (5) | JP6994061B2 (https=) |
| KR (1) | KR20210127197A (https=) |
| CN (2) | CN111568906B (https=) |
| AU (2) | AU2020220957B2 (https=) |
| BR (1) | BR112021015737A2 (https=) |
| CA (1) | CA3130237A1 (https=) |
| CL (1) | CL2021002153A1 (https=) |
| CO (1) | CO2021010689A2 (https=) |
| CR (1) | CR20210428A (https=) |
| EC (1) | ECSP21059628A (https=) |
| IL (1) | IL284628A (https=) |
| JO (1) | JOP20210224A1 (https=) |
| MX (2) | MX2021009704A (https=) |
| MY (1) | MY206327A (https=) |
| PE (1) | PE20212106A1 (https=) |
| PH (1) | PH12021551967A1 (https=) |
| SA (1) | SA521430043B1 (https=) |
| SG (1) | SG11202107259QA (https=) |
| TW (1) | TWI827800B (https=) |
| WO (1) | WO2020165839A1 (https=) |
| ZA (1) | ZA202104594B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210129677A (ko) * | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 안구 표면 통증의 치료 방법 |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| WO2021191273A1 (en) * | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
| WO2022029656A1 (en) * | 2020-08-06 | 2022-02-10 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| WO2022074557A1 (en) * | 2020-10-07 | 2022-04-14 | Novartis Ag | Drug containing dissolvable ocular inserts and method of using same |
| US20230159202A1 (en) * | 2021-11-23 | 2023-05-25 | Bausch + Lomb Ireland Limited | Method for making a preservative-free packaged ophthalmic device product |
| US20240197691A1 (en) * | 2022-12-15 | 2024-06-20 | Cn2 Therapeutics, Inc. | Tacrolimus compositions and methods of use |
| CN118340775A (zh) * | 2023-01-09 | 2024-07-16 | 维眸生物科技(浙江)有限公司 | 一种含vvn539的眼用组合物及其用途 |
| EP4454639A1 (en) * | 2023-04-14 | 2024-10-30 | Omnivision GmbH | Ophthalmic composition comprising carbomer and taurine |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1280874B (de) | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| US3931319A (en) | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4027020A (en) | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| US5037647A (en) | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| JP2003510263A (ja) * | 1999-09-24 | 2003-03-18 | アルコン，インコーポレイテッド | シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物 |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| TWI358290B (en) * | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| BRPI0620264A2 (pt) | 2005-12-22 | 2011-11-08 | Prolexys Pharmaceuticals Inc | quinazolonas aril-substituìdas e sua utilização |
| TW200738232A (en) | 2006-01-31 | 2007-10-16 | Alcon Mfg Ltd | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma |
| EP1964548A1 (en) | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| KR20100039410A (ko) | 2007-07-18 | 2010-04-15 | 노파르티스 아게 | Ｖｒ－１ 길항제 및 ｃｏｘ－２ 억제제의 상승적 조합물 |
| TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| US8163901B2 (en) | 2008-01-09 | 2012-04-24 | Evotec Ag | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| WO2009090548A2 (en) | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| WO2009149239A1 (en) | 2008-06-04 | 2009-12-10 | Children's Medical Center Corporation | Methods of modulating angiogenesis via trpv4 |
| WO2010023512A1 (en) | 2008-08-28 | 2010-03-04 | Matrix Laboratories Ltd. | Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2316420B1 (en) | 2009-10-22 | 2014-02-26 | Consorzio Universitario Unifarm | Topical ophthalmic composition to reduce pain |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| EP2627178B1 (en) | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| CN102659629B (zh) * | 2012-02-14 | 2014-03-19 | 杭州华东医药集团新药研究院有限公司 | 化合物及其在制备埃罗替尼中的用途 |
| CN102875480A (zh) | 2012-04-23 | 2013-01-16 | 中国药科大学 | 喹唑啉酮类血管抑制剂、其制备方法及其医药用途 |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| CA2903114A1 (en) * | 2013-03-15 | 2014-09-25 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
| US20150352176A1 (en) * | 2014-06-06 | 2015-12-10 | Newport Research, Inc. | Oil-free and fat-free aqueous suspensions of cyclosporin |
| EP3179982B1 (en) | 2014-07-28 | 2023-07-19 | Sun Pharma Advanced Research Company Ltd | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| MY196072A (en) * | 2014-09-15 | 2023-03-13 | Verona Pharma Plc | Liquid Inhalation Formulation Comprising RPL554 |
| EP3470059B1 (en) * | 2015-01-26 | 2020-04-01 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
| RU2019110821A (ru) | 2016-09-20 | 2020-10-22 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Антагонисты trpv4 |
| JP2019532054A (ja) | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| KR20210129677A (ko) * | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 안구 표면 통증의 치료 방법 |
-
2020
- 2020-02-12 JP JP2020021093A patent/JP6994061B2/ja active Active
- 2020-02-13 CN CN202010091672.3A patent/CN111568906B/zh active Active
- 2020-02-13 PH PH1/2021/551967A patent/PH12021551967A1/en unknown
- 2020-02-13 SG SG11202107259QA patent/SG11202107259QA/en unknown
- 2020-02-13 KR KR1020217028995A patent/KR20210127197A/ko not_active Ceased
- 2020-02-13 CA CA3130237A patent/CA3130237A1/en active Pending
- 2020-02-13 CN CN202310997308.7A patent/CN117752662A/zh active Pending
- 2020-02-13 US US16/789,976 patent/US11478480B2/en active Active
- 2020-02-13 MX MX2021009704A patent/MX2021009704A/es unknown
- 2020-02-13 AU AU2020220957A patent/AU2020220957B2/en active Active
- 2020-02-13 BR BR112021015737-9A patent/BR112021015737A2/pt unknown
- 2020-02-13 EP EP20708630.7A patent/EP3923912A1/en active Pending
- 2020-02-13 PE PE2021001336A patent/PE20212106A1/es unknown
- 2020-02-13 JP JP2021547131A patent/JP2022520795A/ja active Pending
- 2020-02-13 MY MYPI2021003795A patent/MY206327A/en unknown
- 2020-02-13 WO PCT/IB2020/051211 patent/WO2020165839A1/en not_active Ceased
- 2020-02-13 CR CR20210428A patent/CR20210428A/es unknown
- 2020-02-13 TW TW109104510A patent/TWI827800B/zh active
- 2020-08-24 US US17/000,953 patent/US20200390767A1/en not_active Abandoned
-
2021
- 2021-07-01 ZA ZA2021/04594A patent/ZA202104594B/en unknown
- 2021-07-05 IL IL284628A patent/IL284628A/en unknown
- 2021-08-12 EC ECSENADI202159628A patent/ECSP21059628A/es unknown
- 2021-08-12 JO JOP/2021/0224A patent/JOP20210224A1/ar unknown
- 2021-08-12 SA SA521430043A patent/SA521430043B1/ar unknown
- 2021-08-12 MX MX2024002989A patent/MX2024002989A/es unknown
- 2021-08-13 CL CL2021002153A patent/CL2021002153A1/es unknown
- 2021-08-13 CO CONC2021/0010689A patent/CO2021010689A2/es unknown
- 2021-10-06 JP JP2021164372A patent/JP7465453B2/ja active Active
-
2022
- 2022-09-08 US US17/930,578 patent/US12290517B2/en active Active
-
2023
- 2023-06-21 AU AU2023203933A patent/AU2023203933B2/en active Active
- 2023-12-06 JP JP2023206043A patent/JP2024037806A/ja active Pending
-
2024
- 2024-03-14 JP JP2024039978A patent/JP2024095674A/ja active Pending
-
2025
- 2025-03-21 US US19/087,001 patent/US20260034132A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12290517B2 (en) | Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile | |
| US20240342174A1 (en) | Methods for treating ocular surface pain | |
| RU2853589C2 (ru) | Составы на основе 4-(7-гидрокси-2-изопропил-4-оксо-4h-хиназолин-3-ил)-бензонитрила | |
| RU2850452C2 (ru) | Способы лечения боли на поверхности глаза | |
| KR20260057219A (ko) | 4-(7-히드록시-2-이소프로필-4-옥소-4h-퀴나졸린-3-일)-벤조니트릴의제형 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: BAUSCH + LOMB IRELAND LIMITED (IE) |